Shankar Lal Rampal Dye-Chem Limited (NSE:SRD)
India · Delayed Price · Currency is INR 77.84
-0.55 (-0.70%)
At close: Aug 13, 2025, 3:30 PM IST
Akoya Biosciences Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2017 - 2021 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2017 - 2021 |
Operating Revenue | 4,253 | 4,018 | 2,877 | 3,234 | 3,033 | 1,776 | Upgrade |
Other Revenue | - | - | - | - | 0 | - | Upgrade |
| 4,253 | 4,018 | 2,877 | 3,234 | 3,033 | 1,776 | Upgrade | |
Revenue Growth (YoY) | 28.18% | 39.64% | -11.04% | 6.65% | 70.79% | 33.91% | Upgrade |
Cost of Revenue | 4,013 | 3,790 | 2,714 | 2,893 | 2,594 | 1,599 | Upgrade |
Gross Profit | 240.16 | 228.18 | 163.46 | 341.02 | 438.84 | 177.28 | Upgrade |
Selling, General & Admin | 30.55 | 30.55 | 39.25 | 44.74 | 44.48 | 41.17 | Upgrade |
Other Operating Expenses | 31.2 | 33.08 | 30.03 | 74.46 | 21.61 | 15.05 | Upgrade |
Operating Expenses | 62.81 | 64.66 | 70.17 | 119.9 | 66.6 | 56.68 | Upgrade |
Operating Income | 177.35 | 163.52 | 93.29 | 221.12 | 372.24 | 120.6 | Upgrade |
Interest Expense | -12.87 | -9.24 | -6.02 | -10.42 | -13.45 | -13.33 | Upgrade |
Interest & Investment Income | - | - | 2.56 | 0.41 | 0.36 | 1.14 | Upgrade |
Currency Exchange Gain (Loss) | - | - | 0.1 | 2.47 | -0.36 | - | Upgrade |
Other Non Operating Income (Expenses) | 0.01 | 0.01 | -0.47 | -0.63 | -0.77 | -0.72 | Upgrade |
EBT Excluding Unusual Items | 164.49 | 154.29 | 89.45 | 212.97 | 358.03 | 107.69 | Upgrade |
Gain (Loss) on Sale of Assets | - | - | - | - | - | -0.01 | Upgrade |
Pretax Income | 164.49 | 154.29 | 89.45 | 212.97 | 358.03 | 107.68 | Upgrade |
Income Tax Expense | 43 | 40.37 | 24.48 | 53.87 | 87.38 | 31.35 | Upgrade |
Net Income | 121.49 | 113.92 | 64.97 | 159.09 | 270.64 | 76.33 | Upgrade |
Net Income to Common | 121.49 | 113.92 | 64.97 | 159.09 | 270.64 | 76.33 | Upgrade |
Net Income Growth | 29.50% | 75.35% | -59.16% | -41.22% | 254.59% | 183.22% | Upgrade |
Shares Outstanding (Basic) | 64 | 64 | 64 | 64 | 64 | 64 | Upgrade |
Shares Outstanding (Diluted) | 64 | 64 | 64 | 64 | 64 | 64 | Upgrade |
Shares Change (YoY) | -0.47% | 0.06% | - | -0.02% | 0.03% | 31.63% | Upgrade |
EPS (Basic) | 1.90 | 1.78 | 1.02 | 2.49 | 4.23 | 1.19 | Upgrade |
EPS (Diluted) | 1.90 | 1.78 | 1.02 | 2.49 | 4.23 | 1.19 | Upgrade |
EPS Growth | 30.12% | 75.25% | -59.16% | -41.20% | 254.50% | 115.16% | Upgrade |
Free Cash Flow | - | -126.17 | 54.9 | 143.01 | -171.06 | 100.64 | Upgrade |
Free Cash Flow Per Share | - | -1.97 | 0.86 | 2.24 | -2.67 | 1.57 | Upgrade |
Dividend Per Share | - | - | 0.050 | 0.050 | 0.050 | 0.017 | Upgrade |
Dividend Growth | - | - | - | - | 199.40% | 33.60% | Upgrade |
Gross Margin | 5.65% | 5.68% | 5.68% | 10.54% | 14.47% | 9.98% | Upgrade |
Operating Margin | 4.17% | 4.07% | 3.24% | 6.84% | 12.27% | 6.79% | Upgrade |
Profit Margin | 2.86% | 2.83% | 2.26% | 4.92% | 8.92% | 4.30% | Upgrade |
Free Cash Flow Margin | - | -3.14% | 1.91% | 4.42% | -5.64% | 5.67% | Upgrade |
EBITDA | 178.42 | 164.55 | 94.18 | 221.82 | 372.75 | 121.06 | Upgrade |
EBITDA Margin | 4.20% | 4.10% | 3.27% | 6.86% | 12.29% | 6.82% | Upgrade |
D&A For EBITDA | 1.07 | 1.03 | 0.89 | 0.7 | 0.52 | 0.46 | Upgrade |
EBIT | 177.35 | 163.52 | 93.29 | 221.12 | 372.24 | 120.6 | Upgrade |
EBIT Margin | 4.17% | 4.07% | 3.24% | 6.84% | 12.27% | 6.79% | Upgrade |
Effective Tax Rate | 26.14% | 26.16% | 27.37% | 25.30% | 24.41% | 29.12% | Upgrade |
Revenue as Reported | 4,253 | 4,018 | 2,880 | 3,239 | 3,033 | 1,777 | Upgrade |
Advertising Expenses | - | - | 0.12 | 0.11 | 0.1 | 0.08 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.